drugset / Trial / NCT06238388

Metabolism and Excretory of HSK21542 in Maintenance Hemodialysis Patients

NCT06238388

Phase 1 Completed 6 enrolled Haisco Pharmaceutical Group Co., Ltd.
NaSingle-groupOpen-labelTreatment

Summary

This is a single-center, nonrandomized, and open design study to investigate metabolism and excretion of HSK21542 in maintenance hemodialysis patients.

Timeline

Start
2023-10-10
Primary completion
2023-11-21
Completion
2024-02-27

Drugs

EvaluationDrugModalityDoseRoute
Subject HSK21542 Peptide 0.8 ug/kg Intravenous